ID   XG-1
AC   CVCL_4797
SY   XG1; XG 1
DR   ArrayExpress; E-TABM-937
DR   Cosmic; 742957
DR   Cosmic; 2081411
DR   Cosmic; 2367276
DR   IARC_TP53; 28500
DR   Wikidata; Q54994677
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1753108;
RX   PubMed=7504521;
RX   PubMed=8204890;
RX   PubMed=10087940;
RX   PubMed=10557056;
RX   PubMed=10936422;
RX   PubMed=16956823;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=21173094;
RX   PubMed=30545397;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=XG-1
CC   Characteristics: IL6 dependent.
CC   Characteristics: Produces IgA kappa.
CC   HLA typing: A*02:01,29; B*40,44; C*02:02,16:01 (Direct_author_submission).
CC   Sequence variation: NRAS p.Gly12Arg (c.34G>C) (PubMed=21173094).
CC   Sequence variation: TP53 p.Tyr126Asn (c.376T>A) (ClinVar=VCV000428871) (PubMed=21173094).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis.
CC   Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C.
CC   Derived from sampling site: Peripheral blood.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 17
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1753108;
RA   Jourdan M., Zhang X.-G., Portier M., Boiron J.-M., Bataille R.,
RA   Klein B.;
RT   "IFN-alpha induces autocrine production of IL-6 in myeloma cell
RT   lines.";
RL   J. Immunol. 147:4402-4407(1991).
//
RX   PubMed=7504521; DOI=10.1002/gcc.2870080204;
RA   Raynaud S.D., Bekri S., Leroux D., Grosgeorge J., Klein B.,
RA   Bastard C., Gaudray P., Simon M.-P.;
RT   "Expanded range of 11q13 breakpoints with differing patterns of cyclin
RT   D1 expression in B-cell malignancies.";
RL   Genes Chromosomes Cancer 8:80-87(1993).
//
RX   PubMed=8204890; DOI=10.1182/blood.V83.12.3654.3654;
RA   Zhang X.-G., Gaillard J.-P., Robillard N., Lu Z.-Y., Gu Z.-J.,
RA   Jourdan M., Boiron J.-M., Bataille R., Klein B.;
RT   "Reproducible obtaining of human myeloma cell lines as a model for
RT   tumor stem cell study in human multiple myeloma.";
RL   Blood 83:3654-3663(1994).
//
RX   PubMed=10087940; DOI=10.1016/S0165-4608(98)00157-5;
RA   Kuipers J., Vaandrager J.W., Weghuis D.O., Pearson P.L., Scheres J.,
RA   Lokhorst H.M., Clevers H., Bast B.J.E.G.;
RT   "Fluorescence in situ hybridization analysis shows the frequent
RT   occurrence of 14q32.3 rearrangements with involvement of
RT   immunoglobulin switch regions in myeloma cell lines.";
RL   Cancer Genet. Cytogenet. 109:99-107(1999).
//
RX   PubMed=10557056; DOI=10.1038/sj.leu.2401563;
RA   Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A.,
RA   Shimizu S., Taniwaki M., Ueda R.;
RT   "Detection of MUM1/IRF4-IgH fusion in multiple myeloma.";
RL   Leukemia 13:1812-1816(1999).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=16956823;
RA   Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L.,
RA   Moreau P., Amiot M., Pellat-Deceunynck C.;
RT   "The phenotype of normal, reactive and malignant plasma cells.
RT   Identification of 'many and multiple myelomas' and of new targets for
RT   myeloma therapy.";
RL   Haematologica 91:1234-1240(2006).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T., Ahmann G., Mancini C.,
RA   Brents L.A., Kumar S., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M., Valdez R., Trent J.M., Stewart A.K.,
RA   Carpten J., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=21173094; DOI=10.3324/haematol.2010.033456;
RA   Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D.,
RA   Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "A high-risk signature for patients with multiple myeloma established
RT   from the molecular classification of human myeloma cell lines.";
RL   Haematologica 96:574-582(2011).
//
RX   PubMed=30545397; DOI=10.1186/s13045-018-0679-0;
RA   Tessoulin B., Moreau-Aubry A., Descamps G., Gomez-Bougie P., Maiga S.,
RA   Gaignard A., Chiron D., Menoret E., Le Gouill S., Moreau P., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "Whole-exon sequencing of human myeloma cell lines shows mutations
RT   related to myeloma patients at relapse with major hits in the DNA
RT   regulation and repair pathways.";
RL   J. Hematol. Oncol. 11:137-137(2018).
//